Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
Active, not recruiting · Phase 2 · NCT04703192
Conditions: Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma
At a glance
- Research payments reported, 2025
- $521,701
- U.S. investigators named
- 16
- Sites paid
- 19
- Planned or actual enrollment
- 155
About the trial
- Sponsor
- Daiichi Sankyo
- Tested
- Valemetostat Tosylate (drug)
- Dates
- Started 2021-06-03; completion 2029-06-19
- Results posted
- Yes
This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma, including relapsed/refractory adult T-cell leukemia/lymphoma.
From ClinicalTrials.gov, last updated 2026-11-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $521,701 in research payments for this study in 2025 (314 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Weiyun Z. Ai, MD Medical Oncology · San Francisco, CA
- Alex Herrera, MD Hematology · Duarte, CA
- Niloufer Khan, M.D. Hematology · Duarte, CA
- Monica D. Mead, M.D. Hematology & Oncology · Los Angeles, CA
- Christina Poh, M.D. Hematology · Duarte, CA
- Bradley M. Haverkos, MD Hematology & Oncology · Aurora, CO
- Pamela B. Allen, M.D. Hematology & Oncology · Atlanta, GA
- Eric D. Jacobsen, MD Hematology & Oncology · Boston, MA
- Nabila N. Bennani, M.D. Hematology · Rochester, MN
- Neha Mehta-shah, MD Medical Oncology · Saint Louis, MO
- Tatyana A. Feldman, M.D. Medical Oncology · Hackensack, NJ
- Jason T. Romancik, M.D. Hematology & Oncology · Hackensack, NJ
- Steven Horwitz, MD Medical Oncology · New York, NY
- Jia Ruan, MD, PHD Medical Oncology · New York, NY
- Stefan K. Barta, M.D. Hematology & Oncology · Philadelphia, PA
- Jie Wang, MD Hematology & Oncology · Philadelphia, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Barnes Jewish Hospital, MO $108,799
- Weill Medical College of Cornell University $106,619
- Mayo Clinic Hospital Rochester, MN $52,531
- Hackensack University Medical Center, NJ $33,501
- Regents of the University of Colorado $29,326
- Duke University $28,448
- UCSF Langley Porter Psychiatric Hospital and Clinics, CA $26,826
- Emory University Hospital, GA $26,565
- Memorial Hospital for Cancer and All $24,455
- City of Hope National Medical Ctr $16,915
- Dana-Farber Cancer Institute $16,383
- Duke University Hospital, NC $11,247
- David H Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center $9,691
- Washington University Center for Advanced Medicine $7,738
- UCSF Medical Center, CA $6,930
- Ronald Reagan UCLA Medical Center, CA $5,670
- Washington University $5,598
- Hospital of Univ of Pennsylvania, PA $2,391
- University of Colorado Hospital Authority, CO $2,068
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.